Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, hydroxycarbamide (Siklos®) cannot be endorsed for use within NHS Wales for the prevention of vaso-occlusive crises in patients with symptomatic sickle cell syndrome. |
||
|
||
Medicine details |
||
| Medicine name | hydroxycarbamide (Siklos®) | |
| Formulation | Film-coated tablet | |
| Reference number | 50 | |
| Indication | Prevention of vaso-occlusive crises in patients with symptomatic sickle cell syndrome |
|
| Company | Nordic Pharma UK Ltd | |
| BNF chapter | Nutrition & blood | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 11/10/2010 | |